Achieve Life Sciences (ACHV) Research & Development (2010 - 2026)

Achieve Life Sciences' Research & Development history runs 17 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• Quarterly Research & Development fell 58.08% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (down 30.51% YoY) and the FY2025 annual result came in at $23.0 million, up 0.64% from the prior year.
• Research & Development was $3.0 million for Q1 2026 at Achieve Life Sciences, down from $3.8 million in the prior quarter.
• Across five years, Research & Development topped out at $9.9 million in Q3 2022 and bottomed at $2.1 million in Q4 2023.
• A 5-year average of $5.6 million and a median of $5.3 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development slumped 75.46% — and 2024, when it surged 245.13%.
• Achieve Life Sciences' Research & Development stood at $8.6 million in 2022, then slumped by 75.46% to $2.1 million in 2023, then jumped by 245.13% to $7.3 million in 2024, then plunged by 47.37% to $3.8 million in 2025, then fell by 22.53% to $3.0 million in 2026.
• Business Quant data shows ACHV's Research & Development at $3.0 million in Q1 2026, $3.8 million in Q4 2025, and $5.3 million in Q3 2025.